Search
Atirmociclib
go.drugbank.com/drugs/DB21733InvestigationalAtirmociclib has a monoisotopic molecular weight of 463.18 Da.
Levilimab
go.drugbank.com/drugs/DB16387InvestigationalLevilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant
Epitestosterone
go.drugbank.com/drugs/DB07768ExperimentalEpitestosterone acts as an antiandrogen in various target tissues. The ratio between testosterone/epitestosterone is used to monitor anabolic drug abuse.
INGN 225
go.drugbank.com/drugs/DB05325InvestigationalINGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.
Olenasufligene relduparvovec
go.drugbank.com/drugs/DB16264InvestigationalIt is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.[L46671]
VTX-801
go.drugbank.com/drugs/DB17646InvestigationalVTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the
EGT-301
go.drugbank.com/drugs/DB17649ExperimentalIt consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome
Coagulin-B
go.drugbank.com/drugs/DB17703ExperimentalCoagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.
Lubazodone
go.drugbank.com/drugs/DB09196ExperimentalLubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was